Form 4: Regulus Therapeutics Director Acquires Stock Options

Director Alice Shih-hou Huang receives 30,000 stock options in Regulus Therapeutics.

Summary

• Alice Shih-hou Huang, a director of Regulus Therapeutics Inc., was granted 30,000 stock options on May 16, 2024.
• The options have an exercise price of $2.01.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Ms. Huang directly owns 30,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no red flags or negative implications apparent.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The stock option grant incentivizes the director to work towards increasing shareholder value.

Key Dates